CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy

Harnessing CRISPR-Cas9 technology for cancer therapeutics has been hampered by low editing efficiency in tumors and potential toxicity of existing delivery systems. Here, we describe a safe and efficient lipid nanoparticle (LNP) for the delivery of Cas9 mRNA and sgRNAs that use a novel amino-ionizab...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblum, Daniel, Gutkin, Anna, Kedmi, Ranit, Ramishetti, Srinivas, Veiga, Nuphar, Jacobi, Ashley M., Schubert, Mollie S., Friedmann-Morvinski, Dinorah, Cohen, Zvi R., Behlke, Mark A., Lieberman, Judy, Peer, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673804/
https://www.ncbi.nlm.nih.gov/pubmed/33208369
http://dx.doi.org/10.1126/sciadv.abc9450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673804/
https://www.ncbi.nlm.nih.gov/pubmed/33208369
http://dx.doi.org/10.1126/sciadv.abc9450

Ejemplares similares